Quick Answer
Karyopharm Therapeutics Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $146.07 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed an increase of +0.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $3.0 thousand | Q1 2018: $10.00 million | Q2 2018: $19.89 million | Q3 2018: $239.0 thousand | Q1 2019: $155.0 thousand | Q2 2019: $9.49 million | Q3 2019: $13.15 million | Q1 2020: $18.14 million | Q2 2020: $33.51 million | Q3 2020: $21.33 million | Q1 2021: $23.26 million | Q2 2021: $22.60 million | Q3 2021: $37.69 million | Q1 2022: $47.67 million | Q2 2022: $39.68 million | Q3 2022: $36.15 million | Q1 2023: $38.70 million | Q2 2023: $37.58 million | Q3 2023: $36.01 million | Q1 2024: $33.13 million | Q2 2024: $42.79 million | Q3 2024: $38.78 million | Q1 2025: $30.02 million | Q2 2025: $37.93 million | Q3 2025: $44.04 million.
- Over the full 10 years of available data (2016 to 2025), Karyopharm Therapeutics Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 94,748.7%.
- Historical annual values: Fiscal year 2025: $146.07 million | Fiscal year 2024: $145.24 million | Fiscal year 2023: $146.03 million | Fiscal year 2022: $157.07 million | Fiscal year 2021: $209.82 million | Fiscal year 2020: $108.09 million | Fiscal year 2019: $40.89 million | Fiscal year 2018: $30.34 million | Fiscal year 2017: $1.61 million | Fiscal year 2016: $154.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: